Literature DB >> 18702450

Long-term and per rectum disposition of Clarithromycin in the desert tortoise (Gopherus agassizii).

Jeffrey Wimsatt1, Alysa Tothill, Cord F Offermann, Jenifer G Sheehy, Charles A Peloquin.   

Abstract

The macrolide antibiotic clarithromycin (CLARI) has a wide spectrum of activity and efficacy for Mycoplasma species. In addition, CLARI accumulates during re-dosing of Mojave desert tortoises (Gopherus agassizii). Here, we characterized plasma concentrations after a single dose, after 3.5 months of dosing, and after per rectum administration; all doses were 15 mg/kg. After a single dose, the median maximal plasma concentration (Cmax) was 1.69 mg/ml and occurred at a median of 6 h after administration, the estimated elimination half-life was 6.9 h, and the median accumulation index was 10%. Plasma concentrations after long-term dosing showed consistent intraturtle concentrations of at least 2 microg/ml, with 1 turtle showing increasing accumulation of CLARI at all 3 time points and the remaining 5 turtles showing increases by 3.5 mo. Compared with expected Cmax values, the median long-term values were approximately 3 times higher than expected in 4 of 6 turtles and approximately 2/3 of that expected in the remaining 2 turtles. Per rectum dosing caused antibiotic retention below target values. Together, these results support accumulation of CLARI after repeated oral dosing and indicate that stable concentrations are reached long-term. Either cystoenteric recycling of CLARI or large intestinal absorption of bypass CLARI may explain the observed cumulative increases. In addition, twice-weekly CLARI maintains target concentrations over time, and per rectum dosing will require higher doses or increased dose frequency to be successful. Based on this work, pharmacokinetic studies in exotic species should include multidose studies to verify initial kinetic estimates from single-dose trends.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18702450      PMCID: PMC2694715     

Source DB:  PubMed          Journal:  J Am Assoc Lab Anim Sci        ISSN: 1559-6109            Impact factor:   1.232


  35 in total

1.  New macrolide antibiotics: azithromycin and clarithromycin.

Authors:  H C Neu
Journal:  Ann Intern Med       Date:  1992-03-15       Impact factor: 25.391

Review 2.  Extent and spectrum of the antimicrobial activity of clarithromycin.

Authors:  D J Hardy
Journal:  Pediatr Infect Dis J       Date:  1993-12       Impact factor: 2.129

3.  In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae.

Authors:  K Ishida; M Kaku; K Irifune; R Mizukane; H Takemura; R Yoshida; H Tanaka; T Usui; N Suyama; K Tomono
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

4.  The levels of clarithromycin and its 14-hydroxy metabolite in the lung.

Authors:  D Honeybourne; F Kees; J M Andrews; D Baldwin; R Wise
Journal:  Eur Respir J       Date:  1994-07       Impact factor: 16.671

Review 5.  Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles.

Authors:  M G Sturgill; R P Rapp
Journal:  Ann Pharmacother       Date:  1992-09       Impact factor: 3.154

Review 6.  [Research and development of clarithromycin].

Authors:  S Omura; S Morimoto; T Nagate; T Adachi; Y Kohno
Journal:  Yakugaku Zasshi       Date:  1992-09       Impact factor: 0.302

7.  Treatment of Strongyloides stercoralis hyperinfection syndrome with thiabendazole administered per rectum.

Authors:  D J Boken; P A Leoni; L C Preheim
Journal:  Clin Infect Dis       Date:  1993-01       Impact factor: 9.079

8.  Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses.

Authors:  S Y Chu; L T Sennello; S T Bunnell; L L Varga; D S Wilson; R C Sonders
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

9.  Pharmacokinetics of a clarithromycin suspension in infants and children.

Authors:  V N Gan; S Y Chu; H T Kusmiesz; J C Craft
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

Review 10.  Overview of the tolerability profile of clarithromycin in preclinical and clinical trials.

Authors:  D R Guay; D R Patterson; N Seipman; J C Craft
Journal:  Drug Saf       Date:  1993-05       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.